EASL 2013: Long-term Tenofovir Reduces Liver Cancer Risk in People with Chronic Hepatitis B
- Details
- Category: HBV Treatment
- Published on Friday, 26 April 2013 00:00
- Written by Liz Highleyman
Long-term treatment with tenofovir (Viread) lowered the risk of developing hepatocellular carcinoma among people with chronic hepatitis B, with a notable divergence from expected rates after about 5 years, according to a report presented at the at the EASL International Liver Congress (EASL 2013) this week in Amsterdam.
EASL 2013: International Liver Congress Kicks Off with Hep C New Drug Highlights
- Details
- Category: HBV Treatment
- Published on Wednesday, 24 April 2013 00:00
- Written by Liz Highleyman
The EASL International Liver Congress is now underway at the Amsterdam RAI congress center. At a Wednesday press conference, EASL officials gave a preview of some of the hepatitis C treatment highlights -- both augmentation of interferon-based therapy and interferon-free regimens -- to be presented at the meeting, which runs through Sunday.
EASL International Liver Congress Starts this Week in Amsterdam
- Details
- Category: HBV Treatment
- Published on Monday, 22 April 2013 00:00
- Written by Liz Highleyman
The 
48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013) kicks off this Wednesday, April 24, at the Amsterdam RAI congress center. HIVandHepatitis.com will be on site to provide breaking news and analysis starting later this week.
Heavy Alcohol Use Increases Liver Cancer Risk in Hepatitis B Patients with Cirrhosis
- Details
- Category: HBV Treatment
- Published on Wednesday, 24 April 2013 00:00
- Written by Liz Highleyman
Heavy drinking can add to the already elevated likelihood that people with liver cirrhosis related to hepatitis B virus (HBV) infection will develop hepatocellular carcinoma (HCC), according to a study published in the April 2013 Journal of Hepatology.
Web Design and Development by